By targeting both AKT1 and GAPDH, Nyctanthic acid may offer a more comprehensive therapeutic approach, potentially improving outcomes in oral cancer where resistance and recurrence remain major clinical challenges. This evidence concerns the gene AKT1 and lip and oral cavity carcinoma.